Group 1 - The core viewpoint of the announcement is that the Supervisory Board of the company has reviewed and approved the 2025 semi-annual report and its summary, confirming that the report accurately reflects the company's financial status and operational results for the first half of 2025 [1][2] - The Supervisory Board unanimously agreed that the preparation and review procedures of the semi-annual report comply with relevant laws and regulations, and there are no false records or misleading statements [2] - The company has completed the investment projects funded by the initial public offering, and the special account for raised funds has been closed, ensuring compliance with regulations regarding the use of raised funds [2][3] Group 2 - The Supervisory Board has proposed to cancel the Supervisory Board as part of a decision to enhance the company's governance structure, which aligns with the latest legal requirements and the company's operational needs [3][4] - The cancellation of the Supervisory Board will not harm the interests of shareholders, particularly minority shareholders, and the responsibilities of the Supervisory Board will be transferred to the Audit Committee of the Board of Directors [3][4] - This proposal is subject to approval at the company's shareholders' meeting, and until then, the current Supervisory Board will continue to fulfill its supervisory duties diligently [4]

Core Viewpoint - The company is holding its second extraordinary general meeting of shareholders in 2025 to discuss significant governance changes, including the cancellation of the supervisory board and amendments to the company's articles of association [1][5][7]. Meeting Procedures - The meeting will confirm the identity of attendees and ensure that only registered shareholders or their proxies can participate in voting [2][3]. - The agenda includes the announcement of the number of shareholders present and their voting rights, followed by the reading of meeting guidelines and the election of vote counters [5]. - Shareholders have the right to speak, inquire, and vote, but must register in advance and adhere to time limits during discussions [2][3][5]. Agenda Items - **Proposal 1**: The company proposes to cancel the supervisory board and amend the articles of association accordingly, transferring the supervisory functions to the audit committee of the board [6][7]. - **Proposal 2**: The company aims to revise and establish other operational regulations to align with the updated articles of association and improve governance [7][8]. Voting Process - Voting will be conducted through both on-site and online methods, with specific time frames for participation [4][5]. - The results of the votes will be announced after a break for counting, followed by the reading of the legal opinion by the witnessing lawyer [5][6].

Meeting Overview - The shareholder meeting of Shenlian Biopharmaceutical (Shanghai) Co., Ltd. is scheduled for September 25, 2025 [1] - The meeting will utilize a combination of on-site and online voting methods [1][2] - The on-site meeting will take place at the company's office in Shanghai at 14:30 [1] Voting Procedures - Shareholders can vote through the Shanghai Stock Exchange's online voting system, with voting available from 9:15 to 15:00 on the day of the meeting [1][2] - Specific voting procedures apply to margin trading, transfer, and other related accounts as per the regulations [2] Agenda Items - The main agenda item for the meeting is the proposal to cancel the supervisory board and amend the company's articles of association, which has already been approved by the board and supervisory board [2] - There are no related shareholders that need to abstain from voting on this proposal [2] Attendance Requirements - Only shareholders registered by the close of trading on September 22, 2025, are eligible to attend the meeting [4] - Shareholders must complete registration procedures and present valid identification to participate [4][5] Additional Information - Shareholders are responsible for their own travel and accommodation arrangements for attending the meeting [5] - Contact information for the company is provided for any inquiries related to the meeting [5]

证券代码：688098 证券简称：申联生物 公告编号：2025-032 申联生物医药（上海）股份有限公司 关于召开2025年第二次临时股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 股东大会召开日期：2025年9月25日 本次股东大会采用的网络投票系统：上海证券交易所股东会网络投票系 统 一、 召开会议的基本情况 （一） 股东大会类型和届次 2025年第二次临时股东大会 （二） 股东大会召集人：董事会 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票 相结合的方式 （四） 现场会议召开的日期、时间和地点 召开日期时间：2025 年 9 月 25 日14 点 30 分 召开地点：上海市闵行区江川东路 48 号公司综合楼一楼会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东会网络投票系统 网络投票起止时间：自2025 年 9 月 25 日 至2025 年 9 月 25 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大 ...

申联生物医药（上海）股份有限公司 2025 年第二次临时股东大会会议资料 证券代码：688098 证券简称：申联生物 申联生物医药（上海）股份有限公司 2025 年第二次临时股东大会会议资料 2025 年 8 月 1 申联生物医药（上海）股份有限公司 2025 年第二次临时股东大会会议资料 目录 | 申联生物医药（上海）股份有限公司 年第二次临时股东大会会议须知 3 | 2025 | | | --- | --- | --- | | 申联生物医药（上海）股份有限公司 年第二次临时股东大会会议议程 5 | 2025 | | | 申联生物医药（上海）股份有限公司 年第二次临时股东大会会议议案 7 | 2025 | | | 议案 1：关于取消监事会、修订<公司章程>及附件并办理工商变更登记的 | | | | 议案 | | 7 | | 议案 2：关于修订、制定其他规范运作制度的议案 | | 9 | 2 申联生物医药（上海）股份有限公司 2025 年第二次临时股东大会会议资料 申联生物医药（上海）股份有限公司 2025 年第二次临时股东大会会议须知 为了维护申联生物医药（上海）股份有限公司（以下简称"公司"）全体股 东的 ...

第四届监事会第四次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 证券代码：688098 证券简称：申联生物 公告编号：2025-030 申联生物医药（上海）股份有限公司 1 申联生物医药（上海）股份有限公司（以下简称"公司"）第四届监事会第 四次会议于 2025 年 8 月 29 日以现场结合通讯方式召开，本次会议通知已于 2025 年 8 月 19 日以电子邮件方式送达公司全体监事。本次会议由监事会主席吴守常 先生主持，会议应出席监事 3 名，实际出席监事 3 名，会议的召集和召开程序符 合《中华人民共和国公司法》和《公司章程》等相关规定，会议形成的决议合法、 有效。 二、监事会会议审议情况 （一）审议通过《关于审核公司<2025 年半年度报告>及其摘要的议案》 监事会审核了公司《2025 年半年度报告》及其摘要，了解并监督了半年度 报告的编制及审议程序，全体监事列席董事会并了解董事会对半年度报告的审议 情况。 监事会认为：公司《2025 年半年度报告》及其摘要的编制和审议程序符合 ...

证券代码：688098 证券简称：申联生物 公告编号：2025-029 申联生物医药（上海）股份有限公司 第四届董事会第四次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 申联生物医药（上海）股份有限公司（以下简称"公司"）第四届董事会第 四次会议于 2025 年 8 月 29 日以现场结合通讯方式召开，会议通知于 2025 年 8 月 19 日以通讯方式向全体董事发出。会议应出席的董事 9 名，实际出席的董事 9 名。本次会议的召集和召开程序符合《公司法》和《公司章程》等相关规定， 会议形成的决议合法、有效。 二、董事会会议审议情况 （一）审议通过《关于公司<2025 年半年度报告>及其摘要的议案》 董事会认为：公司《2025 年半年度报告》及其摘要的编制和审议程序符合 相关法律法规和公司管理制度等相关规定，公允地反映了公司 2025 年半年度的 财务状况和经营成果等事项，披露内容真实、准确、完整，不存在虚假记载、误 导性陈述或者重大遗漏。全体董事对《2025 年半年度报告》签署了书 ...

Financial Performance - The company's operating revenue for the first half of 2025 was ¥121,725,138.28, a decrease of 3.68% compared to ¥126,375,941.30 in the same period last year[17]. - The total profit for the period was -¥16,264,533.38, showing an improvement from -¥37,150,792.27 year-on-year[17]. - The net profit attributable to shareholders was -¥12,869,700.94, compared to -¥34,507,973.32 in the previous year[17]. - The net cash flow from operating activities was -¥39,389,053.48, significantly worse than -¥805,633.37 in the same period last year[17]. - The company's total assets at the end of the reporting period were ¥1,536,673,985.58, down 1.12% from ¥1,554,117,949.14 at the end of the previous year[17]. - The net assets attributable to shareholders decreased by 1.03% to ¥1,396,745,623.14 from ¥1,411,295,212.77[17]. - The basic earnings per share for the period was -¥0.03, an improvement from -¥0.08 year-on-year[18]. - The weighted average return on net assets was -0.92%, an improvement from -2.35% in the previous year[18]. Research and Development - The R&D expenditure as a percentage of operating revenue was 22.32%, a decrease of 14.68 percentage points from 37.00% in the previous year[18]. - The company is focusing on research and development, with ongoing progress in its product pipeline and an expansion of its GMP production line types[19]. - The company is committed to developing innovative vaccines and diagnostic products for economic animals, pets, and aquaculture[23]. - The company has a rich pipeline of vaccines and diagnostic products under development, including various vaccines for pigs and cattle[24]. - The company has established five major technology platforms: synthetic peptide technology, genetic engineering technology, new inactivated vaccine technology, nucleic acid (mRNA) technology, and in vitro diagnostic technology, enhancing its core competitiveness in the market[51]. - The company is actively advancing the clinical trial process for its core innovative drugs, UB-421, UB-221, and UB-621, leveraging its management and production capabilities[50]. Market Strategy and Expansion - The company is focusing on expanding its presence in the human innovative drug sector and is exploring a dual-main business model[17]. - The company is strategically adjusting its operations to better align with customer needs and market expansion[19]. - The company is expanding its international business through a "three-step overseas strategy," collaborating on research and development in Southeast Asia, Central Asia, and Africa[35]. - The company is pursuing a strategy of vertical integration in the animal health market and horizontal collaboration in human innovative drugs, creating a differentiated competitive barrier[55]. - The company is enhancing its bacterial vaccine layout through new genetic engineering technologies to meet the increasing demand for bacterial vaccines under the "reduce antibiotics" policy[59]. Financial Investments and Assets - Cash and cash equivalents decreased by 63.70% to ¥53,076,209.98, accounting for 3.45% of total assets[127]. - Trading financial assets increased by 73.19% to ¥75,883,586.11, representing 4.94% of total assets[127]. - Long-term equity investments rose significantly by 1,229.07% to ¥21,034,042.22, now 1.37% of total assets, due to investment in Yangzhou Shizhi Source Biotechnology Co., Ltd.[127]. - Fixed assets increased by 16.40% to ¥734,829,277.67, making up 47.82% of total assets, primarily due to the completion of the animal inactivated vaccine workshop[127]. - The company invested ¥60,000,000 in Yangzhou Shizhi Source Biotechnology Co., Ltd., acquiring a 20.48% stake[134]. Regulatory and Compliance - The veterinary bioproducts industry is regulated by the Ministry of Agriculture and Rural Affairs, with various organizations overseeing technical supervision and industry standards[43]. - The implementation of GMP standards has raised the entry barriers for veterinary bioproduct companies, increasing their operational costs[47]. - The company has established a fundraising management system to ensure that raised funds are used legally and specifically for designated projects[162]. - The company will strictly adhere to all public commitments made during its initial public offering and listing on the Sci-Tech Innovation Board[166]. Corporate Governance and Commitments - The company has reported a commitment to avoid competition with major shareholders and related parties, effective from March 26, 2019, and continuing indefinitely[150]. - The company has committed to reducing and regulating related party transactions, with a commitment period from March 20, 2019, to after departure[150]. - The company guarantees that its controlled enterprises will not engage in any competitive activities with its own business operations[158]. - The company will avoid related party transactions with its subsidiaries and will comply with relevant laws and regulations[160].

申联生物医药（上海）股份有限公司 募集资金管理制度 第一章 总则 第一条 为规范公司募集资金管理，提高募集资金使用效益，根据《中华人民 共和国证券法》《首次公开发行股票注册管理办法》《上市公司证券发行注册管 理办法》《上市公司募集资金监管规则》《上市公司信息披露管理办法》《上海 证券交易所科创板上市公司自律监管指引第 1 号——规范运作》（以下简称"《监 管指引第 1 号》"）《上海证券交易所科创板股票上市规则》（以下简称"《科 创板上市规则》"）等相关法律、法规和规范性文件的规定，制定本制度。 第二条 本制度适用于公司通过发行股票或者其他具有股权性质的证券，向 投资者募集并用于特定用途的资金监管，但不包括公司为实施股权激励计划募集 的资金监管。 第三条 公司募集资金应当专款专用。公司使用募集资金应当符合国家产业 政策和相关法律法规，践行可持续发展理念，履行社会责任，原则上应当用于主 营业务，有利于增强公司竞争能力和创新能力。 公司募集资金应当投资于科技创新领域，促进新质生产力发展。 《监管规则适用指引——上市类第 1 号》对公司发行股份、可转换公司债券 购买资产并募集配套资金用途另有规定的，从其规定。 第四 ...

申联生物医药（上海）股份有限公司 董事、高级管理人员及核心技术人员所持本公司股份及其 第三条 公司董事、高级管理人员及核心技术人员所持本公司股份，是指登记 在其名下的所有本公司股份。 上述人员从事融资融券交易的，还包括记载在其信用账户内的本公司股份。 第四条 公司董事、高级管理人员及核心技术人员委托他人代为买卖公司股 票，视作本人所为，也应该遵守本制度并履行相关询问和报告义务。 第五条 公司董事、高级管理人员及核心技术人员在买卖公司股票及其衍生 品种前，应知悉《公司法》、《证券法》等法律、法规、规范性文件关于内幕交 易、操纵市场等禁止行为的规定，不得进行违法违规的交易。 第六条 公司董事、高级管理人员及核心技术人员就其所持股份变动相关事 项作出承诺的，应当严格遵守。 第二章 股份变动管理要求 第七条 公司董事、高级管理人员所持本公司股份在下列情形下不得转让： 变动管理制度 第一章 总则 第一条 为加强公司董事、高级管理人员所持本公司股份及其变动的管理，根 据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国 证券法》（以下简称"《证券法》"）《上市公司董事和高级管理人员所持本公 司股份及其变 ...